Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Legal and Regulatory Round-up: TriCor Suit Settles, Seroquel Suits Are Tossed, FDA Opens New Post

Executive Summary

Abbott settles TriCor antitrust suit with states: Abbott and its French marketing partner Fournier agreed to pay 24 states and the District of Columbia $22.5 million to settle a suit claiming they blocked generic competition for the cholesterol drug TriCor (fenofibrate) by making minor changes in the formulations to prevent generic substitutions. The 2008 suit also alleged that the companies filed baseless patent infringement suits against Teva and Impax to trigger a 30-month automatic stay of approval (1"The Pink Sheet," March 24, 2008). The Florida Attorney General's Office led the litigation. Last month Abbott settled its patent infringement suit against Teva, allowing Teva to begin marketing its generic fenofibrate in March 2011 (2"The Pink Sheet," Dec. 7, 2009). Direct purchasers had filed a similar TriCor antitrust suit against Abbott, which the company settled in 2008 for $184 million

You may also be interested in...



Namenda Product Hopping Settlement Surpasses Most Recent DOJ Agreements

Direct purchasers' $750m settlement with Allergan is at least the second involving product hopping claims; only one DOJ settlement surpassed this amount in the past year.

Abbott's TriCor Off-Label, Kickback Settlement Is Fraction of 2012 Agreement

$25m settlement resolves allegations covering 2006-2008 period; Abbott inked $1.5bn settlement with government six years ago involving Depakote promotion. This is DOJ's fourth pharma deal of the year.

Abbott TriCor Settlement With Teva Adds Time For Product-Switching

The deal Abbott struck with Teva to allow it to begin selling generic TriCor (fenofibrate) in March 2011 gives Abbott time to convert more patients to its second generation TriLipix (fenofibric acid)

Related Content

Topics

UsernamePublicRestriction

Register

PS051820

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel